Project investment - RunYoung

Vessl

markus.diehl — Fri, 06 Nov 2020 07:30:21 +0000

Vessl’s Medical technology belongs to the field of regenerative medicine and incorporates both cell therapy and gene therapy. Vessl uses vascular endothelial cells to activate genes for therapeutic purposes by growing new compatible vectors/grafts through grafting.

Main product (technology) :

Multi-gene angiogenic growth vectors/grafts (MGAs) for peripheral arterial disease MGAs are formed using endothelial cells activated by the Ang-1 gene in combination with smooth muscle cells activated by the VEGF gene.
Multigene grafts (MGG) for dialysis access. MGG is formed by grafting endothelial cells + polymers activated by the fibulin-5 gene.

The post Vessl appeared first on RunYoung.

BrainQ

markus.diehl — Thu, 05 Nov 2020 07:38:27 +0000

BrainQ is an Israeli company that has developed neuro-recovery technology for various neurological diseases. The core of the company’s technology is related to the identification of high-resolution spectra in brain waves and it has developed the world’s largest database of electroencephalography (EEG) motion tasks for brain-computer interface programs.

The advantages of the company’s therapeutic products include: being small and portable, allowing personalized treatment and real-time optimization treatment plans, the ability to connect to the system control unit locally or via the cloud and allowing patients to be treated in their own wheelchairs.

The post BrainQ appeared first on RunYoung.

Neshima

markus.diehl — Wed, 04 Nov 2020 07:36:11 +0000

Acute respiratory distress syndrome (ARDS) is a lung disease with a high mortality rate and difficult recovery. Pneumonia, inhalation, and drowning are all contributing factors to ARDS. How effectively surfactant is delivered to the lungs is key to alleviating the disease. Currently, due to the lack of effective treatment options for ARDS, care and rehabilitation are entirely dependent on mechanical ventilation. Professor Yan Ostrovski of Israel has developed a liquid foam as a drug carrier based on existing intubation methods, called “liquid foam therapy” (LIFT), in which an automated device pushes the foam into the lungs to distribute it evenly and sufficiently. This method offers advantages such as uniform distribution, unlimited dose, high penetration, and low cost of treatment. It can also be used in the future for lung delivery of stem cells and to address the entire market.

The post Neshima appeared first on RunYoung.

VEGF

markus.diehl — Tue, 03 Nov 2020 07:41:57 +0000

Israeli scientist Eli Keshet discovered that using vascular cell growth factor (VEGF) to help maintain vascular stability can be an effective and comprehensive way to combat aging. Current animal studies have shown that increasing intravascular VEGF levels can effectively reduce a number of problems triggered by aging such as capillary loosening, liver damage, loss of strength, osteoporosis, and tumor risk. The company is currently further investigating the full applicability of this anti-aging therapy, as well as testing the use of specific inhibitors of the VEGF antagonists that the body produces with aging.

The post VEGF appeared first on RunYoung.

AMD

markus.diehl — Mon, 02 Nov 2020 07:40:24 +0000

Dry age-related macular degeneration (AMD) is a chronic neurodegenerative disease that can eventually lead to blindness and cellular senescence of the retinal pigment epithelium (RPE) RPE cells are thought to be an important mediator in the pathogenesis of macular degeneration. Israeli scientist Ayala Pollack and his team have investigated a novel minimally invasive therapy for AMD that affects aging RPE cells using a new compound that specifically interferes with the metabolism of senescent cells and reduces aging phenotypes and complications, thereby acting as a delaying factor for AMD development. It has now been validated in in-vitro and in animal model tests.

The post AMD appeared first on RunYoung.